Member Info for MIKODX

I wouldn't knock Opti, they are good company with products already selling on the market. Although SBTX do not actually have any products on the market, they do have a higher MCAP value and a lot more investor support. Both are good companies, it's just that SBTX has the higher market value and the greater potential.

Looks like ODX and GDR are battling for places again. GDR just slightly ahead. The last time this happened GDR climbed to 160, ODX 115. Hopefully history repeats itself with ODX doing a lot better.

Topped up some more couple days ago @31. Heavily loaded here now. Can't wait for the breakout.

The deeper I've dug into this company, the more impressed I've been with them. 45% of the company is in public hands, the rest are owned by II's and a significant holder Manchester University. With a MCAP of £100M and only 157M shares outstanding the company is in a very healthy and strong position. They have 5M net assets and no debt. With less than ten members of staff, their monthly cashburn is very modest.

What impressed me most is their commercial agreement with Croda International. Croda is a huge company with a MCAP of 9.7B. They already have a strong presence in the Cosmetic market and have hundreds of products already selling all over the world. They also recently won a contract to supply components for the Pfeizer Biontech vaccine a contract worth $125M for the company this year. As well as the Pfezer contract they are also involved in 60 other projects focused on covid-19 vaccines and therapeutic treatments.

SBTX have a very experienced team including Dr Cath O'Neil who is Chief Scientific Officer. She is an accomplished biologist and a leader in human-bacterial interactions, she is also invested in the company. Cath previously founded a specialist dermatology business, Curapel Limited, leading the company through its formation and development stage. As an innovator and expert Cath has worked as an advisor for a number of skincare businesses and brand owners. This includes delivering technology from the lab, through development and onto to new product concepts in partnership with global corporations. Cath is a biochemist by training and has previously led research teams as a senior lecturer at the University of Manchester.

Most of the research on the AxisBiotix-Ps were already completed at Manchester University which is why SBTX has reached production and commercialisation stage so quickly. The treatment is delivered by means of a food supplement shake which is added to water, it has very positive affects on skin conditions such as eczema, acne, and Psoriasis. The product is receiving rave reviews and will be sold in the billions if given the go ahead. This stock has huge potential, who knows where they could be in six months if the product is commercialized.

With significant backing from institutions such as Optibio, University of Manchester, HBOS, AJ Bell, and Barclays bank, the company has huge potential. Might be here for the long haul depending how management shapes up.

Topped up and averaged down, I couldn't hold out any longer. Was trying to get in @65 but the trade volume keeps going up and so does the SP, high trade volumes today. . Was going to wait until Monday to see if things calm down but don't want to take the risk, it could climb higher then it really would cost me. Managed to get in @67 which I'm happy with, thats taken my average down after getting spiked @85. This stock looks like it's ready to breakout, glad to be onboard.

GLA

Please, let's not start that tweet fiasco off again lol.

One more trading day to go, will we get an RNS? CK is known to leave these sort of announcements until the last minute so you never know. Dealing with BJ and the UK Govt was always going to be a bumpy ride at the best of times. Here's hoping.

No I am not a day trader, I have a mixed portfolio. I have stocks that are LT , some ST, and the more volatile stocks I tend to trade. All types of investments provides liquidity for a stock and shouldn't be frowned upon.

letsbecool - You dont make nor lose money in stocks until you sell. Most people invest in S&S to make money whether it takes three months or three years. But what I don't do is stay in a stock forever just to prove my loyalty to a company. If you hold on to a stock forever just to prove how loyal you are to a company then that's on you. I'm here to make money, not make a company my wife.

Rokerpark68 - I'm sure most people including myself would find a broad range of topics on TILS very useful. But let's face it, the Accustem topic has been flogged to death, and has probably scared off investors. Trade volumes has taken a tumble since end of February and this may or may not be the cause. Best to stay positive especially after yesterday's great RNS.

Rokerpark68, whether you like it or not the deal is done, the demerger has happened and no amount of whinging or foot stamping is going to change that. The company has been very generous by giving investors free shares in the company. The IPO hasn't happened yet so all one can do is wait.

You and many others have had plenty of opportunities to get out of this stock if you weren't happy with the demerger but you decided to hold. That is not the fault of the company, that is your own calculated decision. Accustem will be used to test for cancer, and has nothing to do with the products TILS will eventually market, nor the RNS that went out yesterday. The Accustem fiasco is boring and has nothing to do with why most are invested in TILS, time to give it a rest. I'd rather discuss topics that relate directly with what TILS are doing, not Accustem which is a whole different entity.

Yesterday's RNS was a very positive one for the company, investors shouldn't lose sight of that. I've jumped in and out of this stock multiple times and have made very decent gains. I wouldn't put down this company for one second even if I felt the demerger wasn't handled well, which I actually think it was.

What I have noticed though is that trade volumes have decreased and I'm not surprised. The constant whinging about Accustem has scared off investors. Seems like there are a lot of PI's on here self destructing their own investments, who does that? If you don't have anything positive to say about the company your better off not saying anything at all instead of commenting just for the sake of it. Seriously, there are some real sados on here who have nothing better to do than spread their cancerous negativity. Time to put Accustem to bed, it's a done deal. Get over it and get over yourself while your at it.

I find it amazing that people are still crying over Accustem. Most investors weren't even aware of Accustem until the company announced the demerger. The SP has been lower than it is today before the demerger so trying to blame the demerger for the drop in SP is clutching at straws and trying to find blame somewhere. If your not happy where the company are at, then please sell up and do one, you will not be missed.

TILS is debt free and have £50M net assets. How much more healthy can a company be? TILS are moving along nicely, ignore the nay sayers who haven't a clue why they are even invested here.

https://www.omegadiagnostics.com/Products/COVID-19/VISITECT-COVID-19-Antigen

Yes, it looks like this will retrace before it goes back up. I suppose there is a lot of profit taking going on. As I'm new to this share I got spiked this morning @84. Wasn't expecting it to drop down this much after such a good RNS. I dont believe in stop losses so I'm down right now, but have every confidence that this company will soon be manufacturing a great and essential product. Once the profit taking is finished, this should start to climb back up. Might just average down once I do a bit more research.

Holding firmly.

Nasal administration of Foralumab is a unique approach to treat patients with neurodegenerative diseases such as progressive MS , amyotrophic lateral sclerosis (ALS) and Alzheimer's Disease (AD). This study demonstrates for the first-time that nasally administered Foralumab, at the identified optimal dose of 50 mcg/day, induces immunomodulatory effects capable of providing clinical benefit to treated subjects.

These data along with results from our recently completed trial in COVID-19 patients in Brazil suggest a dose-range of 50 mcg-150mcg could be used for future clinical development of nasally administered Foralumab. This is a major accomplishment providing the scientific rationale to move forward with further clinical development of nasally administered Foralumab in patients with neurodegenerative diseases," commented Dr. Howard L. Weiner, Chair of the Scientific Advisory Board of Tiziana Life Sciences and Professor of Neurology at Harvard Medical School. He added that "both oral and nasal administration routes are physiologic approaches to stimulate the mucosal immune system to induce disease modifying immunomodulation. Our immediate focus is on developing Foralumab for treatment of progressive MS.

So we literally have ground breaking treatment for Multiple Sclerosis, Alzeimers, and COVID-19 and people are still complaining. Once this news is properly digested they will all be clammering to get on board.

Holding Firmly

Latest news is great news for the company.

GLA.

Hopefully this stock can get back to where it belongs. Latest RNS is tremendous news for the company.

GLA.

Never seen this train go backwards since I bought in. It either goes up or stays stagnant at 30. A nice steady share that acts like how a stock on the main market should act. I have to keep reminding that them this is not AIM. Wont be long before this share really breaks out.